Alvise Berti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alvise Berti has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Carlo Lombardi
Departmental Unit of Allergology, Immunology & Pulmonary Diseases, Fondazione Poliambulanza, Brescia, Italy
1 shared publication - Cristiano Carbonelli
Home for Relief of the Suffering, San Giovanni Rotondo, Italy, Italy
1 shared publication - Francesco Bini
Regional Health Care and Social Agency Rhodense, Garbagnate Milanese, Italy, Italy
1 shared publication - Francesco Menzella
Pulmonology Unit, S. Valentino Hospital, Montebelluna (TV), AULSS2 Marca Trevigiana, Italy
1 shared publication - Marcello Cottini
Allergy and Pneumology Outpatient Clinic, Bergamo, Italy
1 shared publication - Maria Rita Marchi
Pulmonolgy Unit, ULSS6 Euganea, Cittadella (PD), Italy, Italy
1 shared publication
Latest Publications
- Open Access
- 20 November 2026
- Published by MDPI AG in Preprints.org
Allergic Bronchopulmonary Aspergillosis (ABPA): A Comprehensive Review of Diagnosis, Phenotypes, and Novel Therapeutic Strategies
Allergic bronchopulmonary aspergillosis (ABPA) is a complex, progressive immune-allergic pulmonary disease that primarily affects patients with underlying predisposing conditions such as severe asthma and cystic fibrosis. Triggered by the non-invasive airway colonization of Aspergillus fumigatus, ABPA drives a hyper-amplified Type-2 and epithelial-mediated inflammatory cascade characterized by extreme elevations in total serum immunoglobulin E (IgE), profound local and systemic eosinophilia, and the formation of tenacious, high-attenuation mucus plugs. Historically, diagnostic recognition has been delayed by overlapping clinical features with severe asthma and atypical presentations mimicking thoracic malignancies, leading to irreversible lung injury. However, the revised 2024 International Society for Human and Animal Mycology (ISHAM) criteria, molecular component-resolved diagnostics, rapid on-site evaluation techniques, and the pheno-endotyping framework proposed by the European Academy of Allergy and Clinical Immunology (EAACI) Task Force now facilitate earlier and more accurate identification during the pre-bronchiectatic serological stage. While systemic corticosteroids, triazole antifungals, and airway clearance techniques remain foundational for acute exacerbations, targeted monoclonal antibodies—including anti-IgE, anti-IL-5/IL-5Rα, anti-IL-4Rα, and upstream anti-TSLP agents—have inaugurated a precision medicine paradigm for refractory and steroid-dependent disease. This comprehensive review synthesizes current advances in ABPA immunopathogenesis, diagnostic biomarkers, clinical-radiological phenotyping, and targeted biological strategies, while highlighting ongoing challenges in predictive biomarker validation and individualized biologic sequencing.
- 20 November 2026
- Published by MDPI AG in Preprints.org
Open AccessAllergic Bronchopulmonary Aspergillosis (ABPA): A Comprehensive Review of Diagnosis, Phenotypes, and Novel Therapeutic Strategies
Allergic bronchopulmonary aspergillosis (ABPA) is a complex, progressive immune-allergic pulmonary disease that primarily affects patients with underlying predisposing conditions such as severe asthma and cystic fibrosis. Triggered by the non-invasive airway colonization of Aspergillus fumigatus, ABPA drives a hyper-amplified Type-2 and epithelial-mediated inflammatory cascade characterized by extreme elevations in total serum immunoglobulin E (IgE), profound local and systemic eosinophilia, and the formation of tenacious, high-attenuation mucus plugs. Historically, diagnostic recognition has been delayed by overlapping clinical features with severe asthma and atypical presentations mimicking thoracic malignancies, leading to irreversible lung injury. However, the revised 2024 International Society for Human and Animal Mycology (ISHAM) criteria, molecular component-resolved diagnostics, rapid on-site evaluation techniques, and the pheno-endotyping framework proposed by the European Academy of Allergy and Clinical Immunology (EAACI) Task Force now facilitate earlier and more accurate identification during the pre-bronchiectatic serological stage. While systemic corticosteroids, triazole antifungals, and airway clearance techniques remain foundational for acute exacerbations, targeted monoclonal antibodies—including anti-IgE, anti-IL-5/IL-5Rα, anti-IL-4Rα, and upstream anti-TSLP agents—have inaugurated a precision medicine paradigm for refractory and steroid-dependent disease. This comprehensive review synthesizes current advances in ABPA immunopathogenesis, diagnostic biomarkers, clinical-radiological phenotyping, and targeted biological strategies, while highlighting ongoing challenges in predictive biomarker validation and individualized biologic sequencing.